Therefore, future studies with type 2 diabetes model should be performed with a more detailed experimental design by focusing on the dose-dependent effect of CMD as well as the direct interaction between CMD and netrin-1 or other targets. The gene discussed is NTN1; the disease is type 2 diabetes mellitus.